News

News
Partner news

Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Read full story
Partner news

Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.

Read full story
Partner news

Zebra Medical Vision Announces Agreement With DePuy Synthes to Deploy Cloud Based Artificial Intelligence Orthopaedic Surgical Planning Tools

Read full story
In the media

At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience

Read full story
Partner news

Janssen to Acquire Investigational Bermekimab from XBiotech

Read full story
Other news

Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension

Read full story
Partner news

BiomX Enters Collaboration with Johnson & Johnson Innovation for Discovery of Microbiome-based Biomarkers for IBD

Read full story
Partner news

Vect-Horus Announces Agreement With Johnson & Johnson Innovation

Read full story
JNJ Press releases

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

Read full story
JNJ Press releases

Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

Read full story
JNJ Press releases

Johnson & Johnson Innovation announces winners of the Seoul Innovation QuickFire Challenge in Collaboration with Seoul Metropolitan Government and KHIDI

Read full story
JNJ Press releases

Nico Vandervelpen nominated in Bloomberg50 list

Read full story
JNJ Press releases

Johnson & Johnson Innovation Announces Launch of JLABS @ Shanghai in Collaboration with Shanghai Municipal Government, Pudong New Area Government and Shanghai Pharma Engine Company Ltd

Read full story
JNJ Press releases

eTheRNA joins the JLINX Community

Read full story
Partner news

Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy

Read full story